Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Change in Accured Expenses (2016 - 2026)

Ocular Therapeutix has reported Change in Accured Expenses over the past 14 years, most recently at -$8.4 million for Q1 2026.

  • For Q1 2026, Change in Accured Expenses fell 64.06% year-over-year to -$8.4 million; the TTM value through Mar 2026 reached $2.0 million, down 84.41%, while the annual FY2025 figure was $5.2 million, 44.26% up from the prior year.
  • Change in Accured Expenses for Q1 2026 was -$8.4 million at Ocular Therapeutix, down from $2.2 million in the prior quarter.
  • Over five years, Change in Accured Expenses peaked at $7.9 million in Q2 2024 and troughed at -$14.0 million in Q1 2024.
  • A 5-year average of $168352.9 and a median of $1.9 million in 2022 define the central range for Change in Accured Expenses.
  • Biggest five-year swings in Change in Accured Expenses: soared 930.32% in 2022 and later tumbled 433.9% in 2024.
  • Year by year, Change in Accured Expenses stood at $1.9 million in 2022, then tumbled by 164.33% to -$1.2 million in 2023, then soared by 437.56% to $4.2 million in 2024, then crashed by 48.26% to $2.2 million in 2025, then plummeted by 487.91% to -$8.4 million in 2026.
  • Business Quant data shows Change in Accured Expenses for OCUL at -$8.4 million in Q1 2026, $2.2 million in Q4 2025, and $5.4 million in Q3 2025.